{
    "root": "e4c4122b-6772-46a0-aaaa-3815e6a9736f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atomoxetine",
    "value": "20250326",
    "ingredients": [
        {
            "name": "ATOMOXETINE HYDROCHLORIDE",
            "code": "57WVB6I2W0",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_331697"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "DIMETHICONE, UNSPECIFIED",
            "code": "92RU3N3Y1O",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11074"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        }
    ],
    "indications": {
        "text": "atomoxetine hydrochloride selective norepinephrine reuptake inhibitor indicated treatment attention-deficit/hyperactivity disorder ( adhd ) . ( 1.1 )",
        "doid_entities": [
            {
                "text": "adhd (DOID:1094)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1094"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "initial , target maximum daily dose ( 2.1 ) ( acute maintenance/extended treatment ) body weight initial daily dose target total daily dose maximum daily dose total children adolescents 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg children adolescents 70 kg adults 40 mg 80 mg 100 mg dosing adjustment \u2013 hepatic impairment , strong cyp2d6 inhibitor , patients known cyp2d6 poor metabolizers ( pms ) . ( 2.5 , 12.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "\u2022 hypersensitivity atomoxetine constituents product . ( 4.1 ) \u2022 atomoxetine hydrochloride within 2 weeks discontinuing maoi drugs affect brain monoamine concentrations . ( 4.2 , 7.1 ) \u2022 narrow angle glaucoma . ( 4.3 ) \u2022 pheochromocytoma history pheochromocytoma . ( 4.4 ) \u2022 severe cardiovascular disorders might deteriorate clinically important increases hr bp . ( 4.5 )",
    "indications_original": "Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). (1.1)",
    "contraindications_original": "Initial, Target and Maximum Daily Dose (2.1) (Acute and Maintenance/Extended Treatment) Body Weight Initial Daily Dose Target Total Daily Dose Maximum Daily Dose Total Children and adolescents up to 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg Children and adolescents over 70 kg and adults 40 mg 80 mg 100 mg Dosing adjustment \u2013 Hepatic Impairment, Strong CYP2D6 Inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs). ( 2.5 , 12.3 )",
    "adverseReactions_original": "\u2022 Hypersensitivity to atomoxetine or other constituents of product. (4.1) \u2022 Atomoxetine hydrochloride use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations. ( 4.2 , 7.1 ) \u2022 Narrow Angle Glaucoma. (4.3) \u2022 Pheochromocytoma or history of pheochromocytoma. (4.4) \u2022 Severe Cardiovascular Disorders that might deteriorate with clinically important increases in HR and BP. (4.5)",
    "drug": [
        {
            "name": "Atomoxetine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_127342"
        }
    ]
}